Skip to main content
. 2021 Jan 15;40(8):1516–1530. doi: 10.1038/s41388-020-01627-y

Fig. 6. Exo-counter detection identifies BATF2+EVs in plasma as a novel biomarker of glioma.

Fig. 6

A Representative images of BATF2, CD33, CD14, SDF-1α, and HIF-1α in human malignant glioma tissues from 50 patients. Scale bars, 100 μm. B Correlations analyses of BATF2, CD33, CD14, SDF-1α, and HIF-1α in human malignant glioma tissues from 50 patients. The Pearson’s correlation coefficient (r) and p value are shown (n = 50). C Exo-Counter detection of BATF2+EVs in tumour tissues of I–II GBM, III–IV GBM and healthy donors (n = 5, *p < 0.05, **p < 0.01, ***p < 0.001). D Exo-Counter detection of BATF2+EVs in plasma of I-II GBM, III-IV GBM and healthy donors (n = 24, *p < 0.05, **p < 0.01, ***p < 0.001). E ROC curve of BATF2+EVs numbers data from I–II GBM vs. healthy donors, III–IV GBM vs. healthy donors, I–II GBM vs. III–IV GBM (n = 24, *p < 0.05, **p < 0.01, ***p < 0.001).